PharmExec Blog
Follow Us
RSS
Bookstore
A busy time for Sanofi Sanofi-aventis has agreed to buy Swiss generics firm Helvepharm and has also acquired a controlling stake in the Indian vaccine manufacturer Shantha Biotechnics. Financial details of the Helvepharma deal have not been disclosed but the company is reported to expect sales of 31 million Swiss francs this year. The deal with Shantha has been valued at 550 million Euros and, under the terms of the agreement, Sanofi Pasteur will purchase a holding company that controls 80% of the company from Maerieux Alliance, a French biotech firm.
| WebcastsFree Registration Maximizing Return on Information: A Google Case Study
 Featured Jobs |
The New Health is the fast-morphing world of biopharma: emerging science, changing technology, rising costs, global regulations. The New Health needs an ally. More at www.quintiles.com/newhealth.
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?
Don't miss this Podcast series commemorating the 20th anniversary of HBA's Woman of the Year Award with interviews spanning two decades of change makers.
Super Reps book trilogy by Dr. Lou Sawaya MD, MBA